PHAT

Phathom Pharmaceuticals, Inc. [PHAT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PHAT Stock Summary

Top 10 Correlated ETFs

PHAT

Top 10 Correlated Stocks

PHAT

In the News

PHAT Financial details

Company Rating
-
Market Cap
592.96M
Income
-201.45M
Revenue
682K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
452
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-2.55
Forward P/E
-
PEG
0.8
P/S
-
P/B
-26.61
P/C
-
P/FCF
-3.51
Quick Ratio
8.91
Current Ratio
9.46
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.88
EPS next Y
-
EPS next Q
-
EPS this Y
-31.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
82.89%
-
-
-
-
SMA20
-8.05%
SMA50
-26.41%
SMA100
-19.99%
Inst Own
-
Inst Trans
-
ROA
-78%
ROE
449%
ROC
-0.68%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.065-17.019
52W High
-33.29%
52W Low
+89%
RSI
51.78
Rel Volume
0.86
Avg Volume
917.88K
Volume
786.35K
Perf Week
12.72%
Perf Month
-5.34%
Perf Quarter
-2.58%
Perf Half Y
-7.73%
-
-
-
-
Beta
0.627
-
-
Volatility
0.32%, 0.7%
Prev Close
1.8%
Price
11.34
Change
0.98%

Something similar

Top by Market Cap
ABEC.DE
VTSAX
BRH.DE
TSLA
V
Top Correlated ETFs
PHYD
EWP
EPOL
THD
FDD
Top Correlated Stocks
KRYS
BGN.MI
ADT
ARQT
COFA.PA
Similar Market Cap
RAIL.ST
PRAW.DE
1412.HK
FARO
ULH

Company Profile

Healthcare Biotechnology
  • Volume Average 917.88K
  • Market Capitalization 592.96M
  • Employee 452
  • CEO Ms. Terrie J. Curran
  • Headquarters Florham Park,NJ,US
  • IPO Date 2019-10-25
  • Website https://www.phathompharma.com

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.